FIELD: immunology.
SUBSTANCE: disclosed is use of a pharmaceutical composition containing an effective amount of anifrolumab, for treating systemic lupus erythematosus, myositis, scleroderma, lupus nephritis or cutaneous lupus erythematosus in a subject characterized by an increased expression profile of EPHB2, BLC, LAG-3 and IP-10 proteins.
EFFECT: invention makes it possible to effectively treat a unique subgroup of patients with potentially high activity of IFN type I and low levels of IFN-induced genes in blood.
8 cl, 7 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE CHEMOKINE MODULATION | 2007 |
|
RU2446809C2 |
| BIOMARKERS FOR PREDICTING AND ASSESSING RESPONSIVENESS OF ENDOMETRIAL CANCER SUBJECTS TO LENVATINIB COMPOUNDS | 2014 |
|
RU2658601C2 |
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
| PHARMACODYNAMIC MARKERS, INDUCED BY ALPHA INTERFERON | 2007 |
|
RU2527068C2 |
| INTERFERON ALPHA 1 RECEPTOR ANTIBODIES AND USE THEREOF | 2005 |
|
RU2600884C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERFERON-ALPHA AND APPLICATION METHODS | 2006 |
|
RU2431638C2 |
| METHOD OF DIAGNOSING LUPUS IN HUMAN | 2010 |
|
RU2596391C2 |
| ANTIBODIES OF INTERFERON ALFA RECEPTOR 1 AND THEIR APPLICATION | 2005 |
|
RU2412202C2 |
| DETERMINATION OF DOSE FOR IMMUNOTHERAPEUTIC AGENTS | 2017 |
|
RU2771717C2 |
| HUMANISED ANTI-IL-10 ANTIBODIES FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) | 2010 |
|
RU2581812C2 |
